#AGS24 PLENARY SESSIONS

The following 7 plenary sessions will feature presenters live on camera answering your questions!

THURSDAY, MAY 9

11:15 AM – 12:00 PM EASTERN
PLENARY PAPER SESSION
Track: Research  CME/CE: .75
Sponsored by the Research Committee
Moderator: Mark A. Supiano, MD
This session will present the top three research abstracts based on average score, quality, originality and methodology of research. Learning Objectives: (1) describe emerging concepts or a new scientific focus in aging research; and (2) summarize the key findings of research with relevance to care of older adults.

- **FOXO3 Genotype Mitigates the Effect of Low Bioavailable Testosterone on Mortality: The Kuakini Honolulu Heart Program**
  Ayumi Emily Sakamoto, MD

- **Home Based Primary Care (HBPC) for Independence at Home Qualified (IAHQ) Veterans Lowers Costs and Expands Home and Community Based Services (HCBS)**
  Bruce Kinosian, MD

- **Decision Regret in Patients Considering Implantable Cardioverter Defibrillator**
  Tais Moreira Protasio, MD

12:00 – 1:00 PM EASTERN
NEW ERA OF ALZHEIMER’S DISEASE DIAGNOSIS AND THERAPEUTICS
Track: Clinical Practice  CME/CE: 1.0
Co-Moderators: Esther S. Oh, MD, PhD & Noll L. Campbell, PharmD, MS
Sponsored by the Clinical Research in Dementia Special Interest Group
This program is intended to provide information for health professionals who want to learn more about the anti-amyloid monoclonal antibody (mab) for treatment of early symptomatic Alzheimer’s disease (AD) with focus on lecanemab. Presenters will also discuss donanemab if it is FDA approved by May 2024. Learning Objectives: (1) discuss the evidence and controversies surrounding the new mab AD medications, and how best to choose appropriate patient population, determine therapeutic dose/frequency/duration and monitor for adverse events; (2) review CMS’s approach to addressing access to FDA approved medications and FDA cleared diagnostics, for Medicare beneficiaries with Alzheimer’s disease; (3) describe the current brain health inequities in the United States and how beta anti-amyloid monoclonal antibody treatment will exacerbate these inequities without additional changes to our AD/ADRD prevention, diagnosis and care paradigms; and (4) discuss the healthcare delivery and economic implications of the FDA approval of medications, such as lecanemab, that target a broad population of people at risk or with Alzheimer’s disease.

- **Use of Anti-Amyloid Therapy for Alzheimer’s Disease in Clinical Practice**
  Esther S. Oh, MD, PhD

- **Coverage of FDA Approved Medications and FDA Cleared Diagnostics for Medicare Beneficiaries with Alzheimer’s Disease**
  Shari M. Ling, MD

- **It’s Not Just the $26,500: How Existing Brain Health Inequities Will Be Exacerbated by Beta Anti-Amyloid Monoclonal Antibody Treatment and Real-World Opportunities and Solutions to Address These Challenges**
Abraham A. Brody, PhD, RN, FAAN

Population and Economic Implications Treatment of People with or at Risk for Alzheimer’s Disease
Julie Bynum, MD, MPH

2:30 – 3:30 PM EASTERN
HENDERSON STATE-OF-THE-ART LECTURE: THE GERIATRIC SURGERY VERIFICATION PROGRAM: A JOURNEY TO IMPROVE THE SURGICAL CARE OF OLDER ADULTS
Track: Clinical Practice CME/CE: 1.0
Moderator: Ronnie A. Rosenthal, MS, MD
This session will describe the efforts of the American College of Surgeons (ACS), together with the AGS and the John A. Hartford Foundation, to improve care for older adults considering and having surgery by developing a structured program and measures that address the goals and needs of each individual older adult. Learning Objectives: (1) describe the process used to develop the ACS Geriatric Surgery Verification quality program; (2) describe the measure available through the GSV for tracking the quality of surgical care in older adults; and (3) discuss the importance of having palliative care standards as part of the care of older adults considering or having surgery.

Introduction: The Team and the Groundwork
Ronnie A. Rosenthal, MS, MD

Developing the Standards and Creating a “Program”
Marcia M. Russell, MD

Overcoming the Challenges of Developing the Measures
Thomas N. Robinson, MD

Continuing the Progress: Adding Palliative Care Standards and More
Zara R. Cooper, MD, MSc

FRIDAY, MAY 10

11:15 AM – 12:00 PM EASTERN
THOMAS AND CATHERINE YOSHIKAWA OUTSTANDING SCIENTIFIC ACHIEVEMENT FOR CLINICAL INVESTIGATION AWARD LECTURE:
“GERIATRICIZING” CHRONIC DISEASE RESEARCH: A GERIATRICIAN’S JOURNEY IN COLLABORATIVE RESEARCH
Track: Research CME/CE: .75
Speaker: C. Barrett Bowling, MD, MSPH
To maximize our capacity to provide clinical care for older adults, AGS members have become leaders in age-friendly health systems and expert educators who disseminate geriatric principles to all levels of clinical training. A similar approach to disseminate geriatric principles in chronic disease research is now needed. In his presentation, Dr. Bowling, a geriatrician and chronic disease researcher, will make the case for why aging expertise is essential in chronic disease research, provide examples from his own collaborations outside of geriatrics, and discuss ways to communicate best practices for age-inclusive research to non-geriatrics research teams. Learning Objectives: (1) describe the need for geriatrics in chronic disease research from scientific discovery through clinical implementation; (2) recognize examples of how geriatric principles can guide chronic disease research and support collaborations outside of geriatrics; and (3) communicate best practices for equitable inclusion of old adults in chronic disease research.
1:30 – 2:30 PM EASTERN
PUBLIC POLICY PLENARY
Track: Public Policy CME/CE: 1.0
Description coming soon.

4:00 - 5:30 PM EASTERN
THE EVOLVING DYNAMICS OF ANTICOAGULATION IN OLDER ADULTS
Track: Clinical Practice CME/CE: 1.5
Co-Moderators: Todd P. Semla, PharmD, MS, BCGP, FCCP, AGSF & Michael Steinman, MD
Learning Objectives: (1) discuss anticoagulation and patients with dementia including risks versus benefits in light of new treatments for Alzheimer's disease; (2) review the available anticoagulants, their indications, and advantages and disadvantages from the primary care perspective; and (3) address non-major bleeding in older adults, including the quality-of-life implications it has and clinical strategies to address it.

Anticoagulation and Patients with Dementia Including Risks Versus Benefits in Light of New Treatments for Alzheimer’s Disease
Esther Oh, MD, PhD

Indications, Advantages and Disadvantages of Available Anticoagulants from the Primary Care Perspective
James T. Pacala, MD, MS

Non-Major Bleeding in Older Adults
Anna L. Parks, MD

Live Panel Q & A

SATURDAY, MAY 11

11:15 AM - 12:45 PM EASTERN
GERIATRICS LITERATURE UPDATE: 2024
Track: Clinical Practice CME/CE: 1.5
Speakers: Kenneth Covinsky, MD, MPH; Eric W. Widera, MD & Alexander K. Smith, MD, MS, MPH
The Geriatric Literature Update is always one of the most popular sessions at the annual meeting. The session will focus on the year’s most important published papers. Discussion includes the significance of findings and application to patient care. Learning Objectives: (1) identify areas in clinical medicine where new strong evidence has been uncovered that should affect geriatric practice; (2) describe the results of a critical appraisal of this evidence; and (3) discuss clinical advances in caring for older adults from a review of approximately 30 peer-reviewed journals January-December, 2023.